Advances In Testing Technologies In The $483.8 Million POC Hba1c Testing Market
Technological advances in point of care (POC) hemoglobin (Hb) A1C testing are helping laboratories to conduct the tests more efficiently. Major players in the market are investing in developing advanced technologies to provide fast, accurate results in a short period, thereby helping laboratories to manage the increase in demand for testing. For instance, in June … Continue reading Advances In Testing Technologies In The $483.8 Million POC Hba1c Testing Market Continue Reading


Hofseth BioCare ASA (“HBC”) announces that Health Canada has approved its accelerated phase 2 investigational trial protocol of CARDIO soft gel treatment for patients with Acute Respiratory Distress Syndrome (ARDS) caused by the SARS-CoV-2 virus. The trial will immediately begin recruiting patients from Greater Toronto based hospitals including Mount Sinai Hospital, Toronto. The trial will …